

DAXXIFY[®] ▼

daxibotulinumtoxinA-lanm injection

BY REVANCE[®]

RECONSTITUTION GUIDE



INDICATION

DAXXIFY[®] (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Please see Important Safety Information throughout, including **BOXED WARNING**. ▼


Brought to you exclusively by

TEOXANE

RECONSTITUTION

For every 100-Unit DAXXIFY® vial, reconstitute with 1.2 mL of sterile saline

DOSAGE



Dose per Site

Inject 0.1 mL into 5 injection points for glabellar lines



Total Dose

40U in 0.5 mL total administered in glabellar lines

STORAGE



BEFORE RECONSTITUTION

Store **at room temperature** away from light pre reconstituted (20°C to 25°C).¹



AFTER RECONSTITUTION

Store **refrigerated** for **up to 72 hours** post reconstitution (2°C to 8°C). **Do not freeze.**¹

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Please see additional Important Safety Information throughout.

PREPARATION



1 USE 1.2 ML OF DILUENT

To reconstitute DAXXIFY®, draw up 1.2 mL of sterile saline.



2 CLEAN STOPPER

Clean the exposed rubber stopper on the DAXXIFY® vial with an alcohol swab.



3 INJECT DILUENT SLOWLY

Slowly inject the saline diluent into the DAXXIFY® vial.



4 MIX THE SOLUTION

Swirl gently to ensure mixing.



5 INSPECT THE SOLUTION

The reconstituted solution should be clear to slightly opalescent, colorless, and free of particulate matter. The reconstituted solution may temporarily appear cloudy. **DO NOT USE** if the solution remains cloudy or discolored or contains flakes or particles.



6 READY FOR TREATMENT

Draw an appropriate dose into a new sterile syringe.



IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions Please refer to Boxed Warning for Distant Spread of Toxin Effect.


The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Please see additional Important Safety Information.

PUSH VOLUME BY SYRINGE

0.3 ML SYRINGE


Each increment is 4 units,
0.1 mL and would contain 8U.



20U (0.18 ng of core neurotoxin)
BOTOX® COSMETIC
Reconstituted with 2.5 mL sterile saline† for glabellar lines treatment

2

40U (0.18 ng of core neurotoxin)
DAXXIFY®
Reconstituted with 1.2 mL sterile saline† for glabellar lines treatment‡



Dose per Site

Inject 8 units (0.1mL) into 5 injection points for glabellar lines

Total Dose

40U in 0.5 mL total administered in glabellar lines

IMPORTANT SAFETY INFORMATION (continued)

Adverse Reactions

The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Drug Interactions Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agent interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Please see additional Important Safety Information on next page.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products.

*Representation is of common 1.0 mL syringe but some syringes may label barrels differently (ie, 0.01 mL tick marks represent 1U). Please check your syringe tick marks carefully. †Preservative-free

IMPORTANT SAFETY INFORMATION (continued)

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women. Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide. DAXI-001720.2


DAXXIFY®
daxibotulinumtoxinA-lanm injection
BY REVANCE®

Brought to you exclusively by

 TEOXANE

DAXXIFY 
daxibotulinumtoxinA-lanm injection
BY REVANCE*

This promotional material is intended for healthcare professionals only.

DAXXIFY  (daxibotulinumtoxinA) is indicated for: the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. The treatment of cervical dystonia in adult patients.¹ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions helps to ensure continued safe use of the medicine.

Before prescribing, please review the full Approved Product Information PBS Information: DAXXIFY is not listed on the PBS. Please review the full DAXXIFY[®] Product Information before prescribing. Product Information is available by clicking this link: <http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2024-PI-03110-1>. BoNT/A, botulinum toxin type A; HCl, hydrochloride; TGA, Therapeutic Goods Administration. References: 1. DAXXIFY[®] Approved Australian Product Information. 2. Botox[®] Approved Australian Product Information. BOTOX[®] Cosmetic is a registered trademark of Allergan, Inc. Botox[®] is a registered trademark of Allergan, Inc., an AbbVie company

Daxxify[®] is a registered trademark of Revance Therapeutics, Inc.

Daxxify[®] is exclusively brought to you in Australia by Teoxane Australia Pty Ltd, 9 Cleg St, Artarmon NSW 2064.

Phone: 1800 633 830, Fax: +61 2 9327 4899. ABN 54 634 849 755. DAX25 August 2025.